In the case of radiolabeled prostate specific membrane antigen (PSMA) targeted therapy in patients with metastatic castrate-resistant prostate cancer, the application of PSMA inhibitors such as 2-(phosphonomethyl)pentanedioic acid (PMPA) has been found to reduce off-target radiation to the kidneys [77]. This evidence concerns the gene FOLH1 and prostate carcinoma.